MedTrace Logo

Activity of Pre-Osteoclasts and Osteoclasts Over Time in Postmenopausal Women Treated With Denosumab or Zoledronic Acid

NCT03812367 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2019-06-14

No results posted yet for this study

Summary

This study evaluates how patients treated with denosumab or zoledronic acid for osteoporosis may change the number of peripheral osteoclast precursors and osteoclast activity, and how that may be associated with changes in bone mass.

Conditions

  • Osteoporosis, Postmenopausal

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Nancy Lane, MD · University of California, Davis

Eligibility

Min Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2021-06-01
Completion
2021-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03812367 on ClinicalTrials.gov